Adjuvant therapy of triple negative breast cancer

Edith A. Perez, Alvaro Moreno Aspitia, E Aubrey Thompson, Cathy A. Andorfer

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Patients with the triple negative subtype of breast cancer have an overall poor outcome, with earlier relapses, distinct patterns of metastases, and lack of specific targets for treatment selection. Classification of these tumors has begun to be modified by inclusion of immunohistochemistry for various markers, and gene profiling. Further characterization of this subtype of breast cancer may aid in the identification of new targeted therapies. Anthracyclines and taxanes remain the standard of care in the adjuvant setting. However, novel anti-angiogenesis, anti-tubulin, and DNA repair agents are already under evaluation in (neo) adjuvant trials. Molecular characterization is being included in trials to identify optimal adjuvant strategies. The aim of this manuscript is to review data concerning the molecular characterization of triple negative breast cancers as well as the clinical outcomes of treating patients with existing adjuvant treatments, and to highlight newer adjuvant research strategies in development.

Original languageEnglish (US)
Pages (from-to)285-291
Number of pages7
JournalBreast Cancer Research and Treatment
Volume120
Issue number2
DOIs
StatePublished - Apr 2010

Fingerprint

Triple Negative Breast Neoplasms
Taxoids
Anthracyclines
Tubulin
Standard of Care
DNA Repair
Therapeutics
Immunohistochemistry
Breast Neoplasms
Neoplasm Metastasis
Recurrence
Research
Genes
Neoplasms

Keywords

  • Adjuvant therapy
  • Basal-like breast cancer
  • Breast cancer
  • Triple negative

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adjuvant therapy of triple negative breast cancer. / Perez, Edith A.; Moreno Aspitia, Alvaro; Thompson, E Aubrey; Andorfer, Cathy A.

In: Breast Cancer Research and Treatment, Vol. 120, No. 2, 04.2010, p. 285-291.

Research output: Contribution to journalArticle

@article{89428e3addbc48cc99987921607f915e,
title = "Adjuvant therapy of triple negative breast cancer",
abstract = "Patients with the triple negative subtype of breast cancer have an overall poor outcome, with earlier relapses, distinct patterns of metastases, and lack of specific targets for treatment selection. Classification of these tumors has begun to be modified by inclusion of immunohistochemistry for various markers, and gene profiling. Further characterization of this subtype of breast cancer may aid in the identification of new targeted therapies. Anthracyclines and taxanes remain the standard of care in the adjuvant setting. However, novel anti-angiogenesis, anti-tubulin, and DNA repair agents are already under evaluation in (neo) adjuvant trials. Molecular characterization is being included in trials to identify optimal adjuvant strategies. The aim of this manuscript is to review data concerning the molecular characterization of triple negative breast cancers as well as the clinical outcomes of treating patients with existing adjuvant treatments, and to highlight newer adjuvant research strategies in development.",
keywords = "Adjuvant therapy, Basal-like breast cancer, Breast cancer, Triple negative",
author = "Perez, {Edith A.} and {Moreno Aspitia}, Alvaro and Thompson, {E Aubrey} and Andorfer, {Cathy A.}",
year = "2010",
month = "4",
doi = "10.1007/s10549-010-0736-z",
language = "English (US)",
volume = "120",
pages = "285--291",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Adjuvant therapy of triple negative breast cancer

AU - Perez, Edith A.

AU - Moreno Aspitia, Alvaro

AU - Thompson, E Aubrey

AU - Andorfer, Cathy A.

PY - 2010/4

Y1 - 2010/4

N2 - Patients with the triple negative subtype of breast cancer have an overall poor outcome, with earlier relapses, distinct patterns of metastases, and lack of specific targets for treatment selection. Classification of these tumors has begun to be modified by inclusion of immunohistochemistry for various markers, and gene profiling. Further characterization of this subtype of breast cancer may aid in the identification of new targeted therapies. Anthracyclines and taxanes remain the standard of care in the adjuvant setting. However, novel anti-angiogenesis, anti-tubulin, and DNA repair agents are already under evaluation in (neo) adjuvant trials. Molecular characterization is being included in trials to identify optimal adjuvant strategies. The aim of this manuscript is to review data concerning the molecular characterization of triple negative breast cancers as well as the clinical outcomes of treating patients with existing adjuvant treatments, and to highlight newer adjuvant research strategies in development.

AB - Patients with the triple negative subtype of breast cancer have an overall poor outcome, with earlier relapses, distinct patterns of metastases, and lack of specific targets for treatment selection. Classification of these tumors has begun to be modified by inclusion of immunohistochemistry for various markers, and gene profiling. Further characterization of this subtype of breast cancer may aid in the identification of new targeted therapies. Anthracyclines and taxanes remain the standard of care in the adjuvant setting. However, novel anti-angiogenesis, anti-tubulin, and DNA repair agents are already under evaluation in (neo) adjuvant trials. Molecular characterization is being included in trials to identify optimal adjuvant strategies. The aim of this manuscript is to review data concerning the molecular characterization of triple negative breast cancers as well as the clinical outcomes of treating patients with existing adjuvant treatments, and to highlight newer adjuvant research strategies in development.

KW - Adjuvant therapy

KW - Basal-like breast cancer

KW - Breast cancer

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=77950690621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950690621&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-0736-z

DO - 10.1007/s10549-010-0736-z

M3 - Article

C2 - 20094772

AN - SCOPUS:77950690621

VL - 120

SP - 285

EP - 291

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -